TNFSF10 and cancer: TRAIL–CDK9i completely or nearly completely abolished clonogenic cell survival in cell lines representing all cancer entities tested, including when TRAIL was applied at low concentrations (1–10 ng/ml) and for as short as 24 h (Fig. 1e-g, right panels).